

**PATTERN OF ANTIPHOSPHOLIPID ANTIBODY
SYNDROME IN AIN SHAMS MATERNITY HOSPITAL**

Thesis

Submitted for Partial Fulfillment of the Master Degree In
OBSTETRICS AND GYNECOLOGY

By

ALY MAHMOUD SAMY EL-BALOULY
M.B., B.Ch., 2002

Under Supervision of

PROF. MOHAMED HASAN NASR EL-DIN
Professor of Obstetrics and Gynecology
Faculty of Medicine, Ain Shams University

PROF. MAGD EL-DIN MOHAMED
Professor of Obstetrics and Gynecology
Faculty of Medicine, Ain Shams University

PROF. ABD EL-AZEIM M. AL-HEFNY
Prof. of Internal Medicine, Rheumatology and Immunology
Faculty of medicine, Ain Shams University

Faculty of Medicine
Ain Shams University

2010

Acknowledgement

First and foremost, I feel always indebted to Allah, the Most Kind and Most Merciful.

I'd like to express my respectful thanks and profound gratitude to Prof., Mohamed Hasan Nasr El-Din, Professor of Obstetrics & Gynecology, Ain Shams University, for giving me the honor and great advantage of working under his supervision. His valuable teaching and continuing education to me extend far beyond the limits of this thesis.

My sincere thanks and utmost appreciation are humbly presented to Prof. Magd El-din Mohamed, Professor of Obstetrics & Gynecology, Ain Shams University, for his meticulous supervision, professional experience and tremendous assistance. It has been a long trip with him in my career. I really appreciate his patience and support.

I am deeply grateful to Prof. Abd El-Azeim M. Al-Hefny, Professor of Internal Medicine, Rheumatology and Immunology, Ain Shams University, for his close supervision, brotherly advice and continuous enthusiastic support

My deepest gratitude I extend to my whole family who offered me support, advice and motivation.

List of abbreviations

aCL.....	anticardiolipin
APASS.....	Antiphospholipid Antibody Stroke Study (APASS) Group.
APCs.....	Antigen-Presenting Cell(s)
aPL.....	Antiphospholipid antibodies.
APS.....	Antiphospholipid syndrome.
APSN.....	Antiphospholipid syndrome nephropathy
ARDS.....	Adult respiratory distress syndrome.
B ₂ -GPI.....	Beta-2 glycoprotein-1.
Be-1, Be-2.....	B. effector 1, 2
C5aR.....	Complement 5a receptor.
CAPS.....	Catastrophic antiphospholipid syndrome.
CD5.....	Cluster of differentiation
CNS.....	Central nervous system.
CTL.....	Cytotoxic T-cell
CVA.....	Cerebral vascular attack.
HELLP.....	Hemolysis, elevated liver enzymes, low platelets syndrome.
HIT/T.....	Heparin induced thrombocytopenia and/or thrombosis syndrome.
HIV.....	Human immunodeficiency virus.
HSP.....	Heat shock proteins.
HUS.....	hemolytic uremic syndrome
ICAM- I.....	Intracellular adhesion molecule-1.
IFN α	interferon alpha
IL.....	interleukin
INR.....	International Normalization Ratio
IUGR.....	Intrauterine growth retardation.
LA.....	Lupus anticoagulant.
LA.....	Lupus anticoagulants.
LDL.....	Low-density lipoproteins.

MHC.....Major histocompatibility complex
MRI.....Magnetic resonance imaging.
MS.....Multiple sclerosis.
NF-Kappa B.....Nuclear factor-Kappa B
oxLDL.....Oxidized low-density lipoproteins.
PAPS.....Primary antiphospholipid syndrome.
SAPS.....Secondary antiphospholipid syndrome.
SIRS.....Systemic inflammatory response
SLE.....Systemic lupus erythematosus.
sTF.....Soluble-TF.
TE.....Thromboembolism.
TF.....Tissue factor.
TFPI.....Tissue factor pathway inhibitor.
TGF- βTumor like growth factor
Th-1.....T-helper 1.
Th-2.....T-helper 2.
TIAs.....Transient ischemic attacks.
TLRs.....Toll like receptors.
TMHA.....Thrombotic microangiopathic hemolytic anemia.
TMN.....Thrombotic microangiopathy
Treg.....T-regulatory cells.
TTP.....Thrombotic thrombocytopenic purpura.
VCAM-1.....Vascular cell adhesion molecule-1.
VTE.....Venous thromboembolism.

Contents

	Page
Introduction.....	1
Aim of the Work	3
Review of literature	4
<i>Chapter 1:</i> The Immune System	4
<i>Chapter 2:</i> Antiphospholipid Antibody Syndrome.....	22
Subjects and methods	76
Questionnaire.....	79
Results	83
Discussion.....	121
Summary	137
Conclusion	141
Recommendations.....	142
References	143
Arabic summary.....	

List Of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page</i>
1	Methods of detection of antiphospho- lipid antibodies	28
2	Opposing effects of antiphospholipid antibodies on coagulation.....	29
3	Criteria for APS diagnosis [Sapparo criteria]	40
4	Disease predisposing to thrombo- embolism	61
5	Disorders during pregnancy for which antithrombotic therapy is commonly considered	74
6	Management of aPL-Positive patients during pregnancy.....	74
7	Recommended therapeutic Doses of LMWH from Controlled Studies in Medical Patients.....	75
8	Distribution of the studied cases as regards year of incidence.....	84

List Of Tables *(Cont..)*

<i>Table No.</i>	<i>Title</i>	<i>Page</i>
9	Demographic data of the patients in the study	86
10	Delivery frequencies in the population of the study	87
11	Abortion frequencies in the population the study	88
12	The menstrual characters of the population of the study.....	90
13	Frequency of contraception use in the population of the study.....	92
14	Indications of hospitalization in the population of the study.....	93
15	Fullfillment of Clinical picture in medical records	95
16	Associated medical disorder	99
17	Descriptive Statistics of laboratory data that was found in medical records.....	100

List Of Tables *(Cont..)*

<i>Table No.</i>	<i>Title</i>	<i>Page</i>
18	Distribution of the studied case as regard immunological markers.....	101
19	Type of heparin used among patients of the study	102
20	The mode of delivery or abortion in the population of the study.....	103
21	Fetal ultrasound findings in patients of the study	105
22	Neonatal ICU admission of the newborns of APS patients.....	106
23	Indications of maternal ICU admission in the population of the study.....	107
24	The ranks of the participant obstetricians	108
25	The awareness of the obstetricians about APL syndrome.....	109
26	Distribution of the doctor's awareness ...	110
27	Comparison of pregnancy outcomes in first admissions versus readmissions.....	111

List Of Tables *(Cont..)*

<i>Table No.</i>	<i>Title</i>	<i>Page</i>
28	Relation between APS with SLE and fetal outcome.....	113
29	Relation between cause of maternal admission and fetal outcomes.....	114
30	Comparative relation between laboratory findings and fetal outcomes..	115
31	Comparison of the questionnaire scores among different obstetricians ranks.....	116
32	Relation between obstetrician's awareness and ICU admissions in the population of the study.....	118
33	Relation between obstetrician's awareness and fetal outcome	119

List Of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page</i>
1	Regulation of the immune system, emphasizing a pivotal role of the helper T cell and MHC.....	5
2	Th1/Th2 paradigm in the maternal deciduas after fetal trophoblast invasion showing effect of progesterone over uteine natural killer cells (uNK) and actions of Tumor like growth factor (TGF- β)	8
3	Antiphospholipid antibody determination by lupus anticoagulant	25
4	Antiphospholipid antibody determination by enzyme-linked immunosorbent assay.....	26
5	Pathogenic mechanisms in antiphospholipid syndrome	27
6	Cascade of reactions during activation of the classic pathway of complement	33
7	Complement mediated hemophilia and fetal loss	34

List Of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page</i>
8	Livedo reticularis	55
9	Flow chart of the two arms of the study .	84
10	Total number of admitted patients in the studied years and the number of patients who had APS among them	85
11	Distribution of the menstrual charac- ters of the studied case.....	91
12	Distribution of the studied cases as regard contraception history.....	92
13	Distribution of the studied cases as regard indication of hospitalization.....	94
14	The clinical pathway of the 90 admitted cases with APS	97
15	Distribution of mode of delivery and abortion in the population of the study ..	104
16	Distribution of obstetricians whom done the questionnaire.....	108
17	Distribution of pregnancy outcomes in 1st and last admissions	112

INTRODUCTION

The antiphospholipid antibody syndrome (APS) is defined by two major components: Presence in the plasma of at least one type of autoantibody known as an antiphospholipid antibody (aPL), and the occurrence of at least one clinical feature from a diverse list of potential disease manifestations. The most common of these clinical manifestations are categorized as venous or arterial thromboses, recurrent fetal loss, or thrombocytopenia (*Bonnie et al., 2009*).

Antiphospholipid antibodies are not directed against phospholipids, as the name of the syndrome would suggest, but against plasma proteins with affinity for anionic phospholipids (*Jane et al., 2009*).

Definite APS or the preliminary classification criteria for definitive antibody (AB) at a post-conference workshop in 1999 in Sapporo, Japan, following the 5th international symposium on aPL. Antiphospholipid antibodies such as lupus anticoagulants (LAs) and anticardiolipin (aCL) are mainly determined as part of the diagnostic work up of patients who are suspected to suffer from APS (*Wilson et al., 1999*).

An association between circulating maternal aPL antibodies and recurrent pregnancy loss has been investigated for many years, and various interventions have been recommended to assist in the maintenance of pregnancy until delivery of a live infant (*Nowak et al, 2009*).

Women who have prior thrombosis must be anticoagulated throughout pregnancy because the risk of new thrombosis markedly increases both during pregnancy and post partum. In these women warfarin is changed to heparin or low-molecular-weight heparin (*Lockshin, 2001*).

AIM OF THE WORK

The objective of this study is assessment of Antiphospholipid syndrome patients in Ain Shams Maternity Hospital during the period of the last five years from January 2004 till January 2009 and the awareness of the physicians as regard their knowledge of this syndrome.

Chapter 1

THE IMMUNE SYSTEM

The major histocompatibility complex (MHC) is a region on the short arm chromosome 6 in which the genes are located that encode antigens that provoke strong rejection reactions. The antigens are called the Human Leukocytic Antigens (HLAs) because they were first thought to occur only on leucocytes. Although the MHC was first identified through its role in graft rejection, its true physiological role lies in the process of immune regulation and antigen recognition by T-cells. Within the MHC there are at least four major subregions or subloci called HLA-A, -B, -C and -DR. At each gene locus there are many different alternative genes or alleles, which result in an enormous diversity or polymorphism (*Peltier et al., 2003*).

Antigen is taken up by Antigen-Presenting Cell(s) (APCs) in the circulation, or resident in lymphoid organs: the APCs process the antigen and present it to the the T-helper cells (Th-cells). The APCs also release cytokines Interleukin-1 (IL-1) which stimulate T-cells and induce IL -2 receptor expression